- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07691138
Stopping PPI Therapy in Inactive IBD (STOP-IT)
STOpping PPI Therapy in Inactive IBD Study (STOP-IT): A Feasibility Study
To investigate the feasibility of proton pump inhibitor (PPI) withdrawal in inflammatory bowel disease (IBD); the data collected will provide valuable information to inform a future multi-centre randomised controlled trial.
Evidence suggests that patients with IBD taking PPIs respond less well to medication and require hospital treatment more frequently than patients not taking PPIs. This may be due to changes in the gut microbiota associated with PPI use.
A future definitive trial is planned to investigate clinical outcomes in patients who stop PPIs compared with those who continue PPIs, in order to determine the safety implications of PPI use in IBD. However, several uncertainties remain which require investigation before such a trial can be undertaken. It is currently unknown how many patients with IBD take PPIs, how many can successfully stop taking PPIs, how many would be willing to stop treatment, and how many would remain off treatment long term. In some cases, withdrawal of PPIs may result in a short-term increase in acid reflux symptoms. The willingness of patients to participate in such a study is also unknown. This study will be conducted in GP practices, a setting in which IBD trials have not previously been undertaken.
The study will recruit 80 participants with IBD aged 16 years and over who have been taking PPIs regularly for more than six months. Half of participants will be randomised to discontinue PPI therapy. Participants will be followed up for 12 months. The study will provide information regarding recruitment rates within GP practices, optimal methods for PPI withdrawal, and whether stopping PPIs affects IBD outcomes.
연구 개요
상세 설명
PURPOSE
The purpose of this study is to explore the feasibility of proton pump inhibitor (PPI) withdrawal in patients with IBD in order to inform the running of a larger scale study.
PRIMARY OBJECTIVES
To understand the feasibility of PPI withdrawal in order to inform a future definitive multi-centre randomised controlled trial by investigating:
How many patients are eligible for this study. What the recruitment rate is - baseline variables predicting non-recruitment from screened patients will be investigated.
What adherence to PPI withdrawal and continuation is - non-adherence amongst recruited participants will be investigated.
What the retention of participants throughout the follow-up period of the trial is.
SECONDARY OBJECTIVES
What is the effect of PPI withdrawal on IBD disease activity?
Effect of withdrawal: For ulcerative colitis, a standardised patient-reported outcome quantifying stool frequency and rectal bleeding scores will be collected. For participants with Crohn's disease, a standardised patient-reported outcome quantifying abdominal pain and stool frequency scores will be collected. Moreover, participants will also be asked to complete the Gastrointestinal Symptom Rating Scale (GSRS) and the Glasgow Dyspepsia Severity Score (GDSS).
TRIAL DESIGN
Parallel-group, open-label randomised controlled trial recruiting participants from primary care. This is an open-label study as it is not possible to blind the clinician delivering the intervention, i.e. the withdrawal of PPI, nor the participant receiving the intervention.
Qualitative study: A semi-structured interview study will be undertaken to investigate the acceptability of and adherence to the study protocol. Interview duration will be up to one hour and will take place online via MS Teams. This may also be available to take place in person, should the participant request this instead. This will allow for further understanding of the underlying mechanisms impacting the study outcomes. This will help inform recruitment processes for downstream research proposals, improving recruitment and attrition. Interviews will follow a semi-structured interview schedule to gain greater clarification through exploration of detailed descriptions of the desired topic from participants. A sample size of approximately 20 participants was chosen. The adequacy of the final sample size will be continually assessed during the data collection process using factors of both 'data saturation' and 'information power'. Data collection and transcription will be undertaken in parallel, and NVivo 12 software will be used to aid data analysis.
RANDOMISATION AND BLINDING
The Randomisation Scheme
Participants will be randomly assigned in a 1:1 ratio to one of two study arms using a random minimisation algorithm, stratified by IBD type (50% Crohn's disease, 50% ulcerative colitis), and current use of advanced therapy (yes/no). Randomisation will be conducted through an online randomisation system, with participants allocated to one of the following groups:
Continue PPI therapy
Withdraw PPI therapy
The randomisation system will be provided by the Derby CTSU. Randomisation will be undertaken by the University of Nottingham research team using the online randomisation tool 'Sealed Envelope' hosted by Derby CTSU. Participants will be contacted by the research team at the University of Nottingham by phone or email to explain their treatment allocation. Participants will also receive a letter via DocMail to confirm their treatment allocation, and a letter (sent via electronic mail) will be sent to the GP explaining participant enrolment and treatment allocation for entry into the medical records.
This is an open-label study as it is not possible to blind the clinician delivering the intervention, i.e. the withdrawal of PPI. The data analyses will be undertaken by the research team, who will be blinded to participant allocation.
TRIAL MANAGEMENT
The trial will be managed by the study team at the University of Nottingham. There is a Trial Manager based at the University of Nottingham.
Derby CTSU will provide a web-based randomisation service and statistical services during the development, conduct, analysis and reporting stages of the feasibility trial. TCR Nottingham will be responsible for setting up the study database and data management while the team at the University of Nottingham will lead trial management, qualitative analyses and overall project delivery.
The TMG will report to the independent TSC, which will be responsible for oversight of the trial including safety oversight. Membership will include patient representation and relevant expertise. The TSC will meet (in person) prior to commencement of the trial to agree the protocol, and then at least annually (in person or by telephone conference) until completion of the trial. The TSC will be responsible for approving the trial protocol, reviewing trial progress and resolving problems brought to it by the co-ordinating centre. Reflecting the feasibility nature of this study, there will be no data monitoring committee.
The Chief Investigator has overall responsibility for the study and shall oversee all study management.
The data custodian will be the Chief Investigator.
DURATION OF THE TRIAL / STUDY AND PARTICIPANT INVOLVEMENT
Participant Duration: From the point of enrolment, participants will be invited to take part in the study for 12 months. Follow-up time points are questionnaire completion at 3, 6 and 12 months and these will be undertaken online or over the phone. Data related to outcomes 3-6 will be collected at these time points. After 3 months in the trial, participants will be invited to take part in the qualitative sub-study, which is a one-off qualitative interview study of up to one hour duration. Participants reach the end of their study participation after their month 12 follow-up is complete.
Study Duration: The planned total study duration is 24 months.
End of the Trial
Once the last 12-month follow-up is completed, the qualitative interviews for those participants who adhered to the study protocol will take place. Therefore, the end of the study is the last interview of the last fully completed participant.
SELECTION AND WITHDRAWAL OF PARTICIPANTS
Recruitment
Routinely collected data will be used to identify patients, making this data-driven trial cost-effective.
연구 유형
등록 (추정된)
단계
- 4단계
연락처 및 위치
연구 연락처
- 이름: Gordon W Moran, MD, PhD
- 전화번호: 80608 0115 9249924
- 이메일: Gordon.moran@nottingham.ac.uk
연구 장소
-
-
-
Nottingham, 영국
- 모병
- University of Nottingham
-
연락하다:
- Gordon W Moran, MD, PhD
- 전화번호: 80608 0115 9249924
- 이메일: Gordon.moran@nottingham.ac.uk
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 어린이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
설명
Inclusion Criteria:
- Aged 16 years or older.
- An IBD diagnosis as defined through SNOMED codes in primary care databases [Appendix 5]
- Taking a PPI regularly for >6 months prior to enrolment
- Patient-confirmed compliance with PPI therapy (>75% of prescribed doses)
- Able to give full, independent valid Informed consent
- Stable disease as defined by no change in medication or IBD-related surgery for the last 3 months.
Exclusion Criteria:
- Unable to participate fully in all aspects of the clinical trial.
- Barrett's oesophagus
- Peptic disease at a recent upper GI endoscopy
- Zollinger-Ellison Syndrome
- Eosinophilic oesophagitis
- Chronic NSAID usage
- Pulmonary fibrosis.
- Declined consent to data sharing
- History of dementia
- Terminal illness
- Present malignancy
- Active history of mental illness
- In a care home
- Alcohol misuse
- Illicit drug misuse
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Continue PPI Therapy
|
Continue PPI therapy
|
|
실험적: Withdraw PPI Therapy
|
Withdraw PPI Therapy
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Eligibility rate
기간: 12 months
|
The proportion of screened patients meeting the study eligibility criteria.
|
12 months
|
|
Recruitment rate
기간: 12 months
|
The proportion of eligible patients who consent to participate in the study.
Baseline variables associated with non-recruitment among screened patients will also be explored.
|
12 months
|
|
Adherence to allocated intervention
기간: 12 months
|
The proportion of participants adhering to their allocated treatment strategy (PPI withdrawal or PPI continuation).
Factors associated with non-adherence will be explored.
|
12 months
|
|
Participant retention rate
기간: 12 months
|
The proportion of recruited participants who complete study follow-up.
|
12 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Effect of PPI withdrawal on inflammatory bowel disease activity in participants with ulcerative colitis
기간: 12 months
|
For participants with ulcerative colitis, disease activity will be assessed using a patient-reported outcome measuring stool frequency and rectal bleeding scores.
|
12 months
|
|
Effect of PPI withdrawal on inflammatory bowel disease activity in participants with Crohn's disease
기간: 12 months
|
For participants with Crohn's disease, disease activity will be assessed using a patient-reported outcome measuring abdominal pain and stool frequency scores.
|
12 months
|
|
Gastrointestinal symptoms measured using the Gastrointestinal Symptom Rating Scale (GSRS)
기간: 12 months
|
The Gastrointestinal Symptom Rating Scale (GSRS) is a 15-item patient-reported questionnaire assessing gastrointestinal symptoms across five domains: abdominal pain, reflux, indigestion, diarrhoea and constipation.
Each item is scored from 1 to 7, resulting in an overall score ranging from 1 to 7, where higher scores indicate worse gastrointestinal symptoms
|
12 months
|
|
Dyspepsia symptoms measured using the Glasgow Dyspepsia Severity Score (GDSS)
기간: 12 months
|
The Glasgow Dyspepsia Severity Score (GDSS) is a patient-reported measure of dyspepsia severity with scores ranging from 0 to 20, where higher scores indicate more severe dyspeptic symptoms.
|
12 months
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- 25053
- 1013002 (기타 식별자: IRAS Project ID)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
The data will be shared with and analysed only by staff from the University of Nottingham and Derby CTSU De-identified pre-analysed data may be shared with collaborators at other UK institutions for the purposes of writing up results and dissemination. All transfers will be via encrypted file transfer.
Data generated as part of the outputs of the project (published manuscripts, published protocols) will be freely available and appropriately licensed for re-use under a CC-BY or CC-BY-NC licence.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .